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Shigella is a pathovar of Escherichia coli comprising four groups, Shigella flexneri, Shigella
sonnei, Shigella dysenteriae, and Shigella boydii, each of them, with the exception of
S.sonnei, comprising several serotypes. Shigella accounts for the majority of dysentery
causing infections occurring world-wide each year. Recent advancements in the Shigella
field have led to a better understanding of the molecular mechanisms underlying host
epithelial cell invasion and immune cell function manipulation, mainly using S. flexneri
as a model. Host-cell invasion is the final step of the infection process, as Shigella’s
virulence strategy relies also on its ability to survive hostile conditions during its journey
through the gastro-intestinal tract, to compete with the host microbiota and to cross the
intestinal mucus layer. Hence, the diversity of the virulence strategies among the different
Shigella species has not yet been deeply investigated, which might be an important
step to understand the epidemiological spreading of Shigella species worldwide and
a key aspect for the validation of novel vaccine candidates. The recent development
of high-throughput screening and sequencing methods will facilitate these complex
comparison studies. In this review we discuss several of the major avenues that the
Shigella research field has taken over the past few years and hopefully gain some insights
into the questions that remain surrounding this important human pathogen.
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INTRODUCTION
Shigella are Gram-negative pathogenic enterobacteria and the etiological agent of bacillary
dysentery or shigellosis. In humans, Shigella specifically invade and colonize the colonic mucosa
leading to its disruption. Shigellosis is associated with fever and abdominal cramps; its diagnosis
relies on the presence of erythrocytes, polymorphonuclear neutrophils (PMNs), and mucus in
patient stools, which stand as diagnostic elements.
Shigella encompasses four subgroups (S. flexneri, S. sonnei, S, dysenteriae, and S. boydii),
each composed of different serotypes, which are identified based on the structure of the
lipopolysaccharide O-antigen repeats: S. dysenteriae encompasses 15 serotypes, S. flexneri, 14
serotypes, S. boydii, 20 serotypes, and S. sonnei a single serotype (Figure 1; reviewed in Marteyn
et al., 2012). Chantemesse and Widal first described the bacillus causing non-amoebic dysentery in
1888, while Shiga first identified S. dysenteriae in 1898 (Shiga, 1898). Flexner first characterized S.
flexneri in 1900 and S. sonnei was isolated and characterized by Sonne (1915). S. boydii was first
described by Boyd in 1931.
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FIGURE 1 | Comparison of selected Shigella O-antigen side chains.
Schematic of repeated O-antigen side chains from serotypes S. sonnei
(Gamian and Romanowska, 1982), S. flexneri 5a (Perepelov et al., 2010), S.
dysenteriae 1 (Dmitriev et al., 1976), and S. boydii 6 (Senchenkova et al.,
2005). Figure legend abreviations are as follows
2-Acetamido-2-deoxy-D-glucose (D-GlcNAc),
2-Acetamido-2-deoxy-L-altruronic acid (L-AltNAc), 2-Acetamido-4-amino-2,
4-dideoxy-D-fucose (D-FucNAc), 2-Acetamido-2-deoxy-D-galacturonic acid
(D-GalNAc), D-Galactopyranose (D-Gal), D-Mannose (D-Man), L-Rhamnose
(L-Rha), D-Glucose (D-Glc), O-acetyl (Ac).
Studies of host-pathogen interactions have mostly been
restricted to the direct contact with and invasion of the host
epithelial and immune cells. This is particularly true in the
Shigella field. Its adhesion and invasion of host cells and
its intracellular life have been characterized at a molecular
level (reviewed in Tran Van Nhieu et al., 2000; Phalipon and
Sansonetti, 2007). In this review, we envisage the host-pathogen
interaction with a more global perspective, considering that prior
to challenging epithelial or immune cells, Shigella must first
interact and compete with the microbiome and subsequently
face a thick mucus layer protecting the colonic epithelium.
Shigella virulence mechanisms involved in these latter aspects
have been under evaluated, although they represent key and
essential features of a successful infection process.
Shigella virulence mechanisms have been mostly identified
and characterized using S. flexneri as a model, while other
groups show significantly high prevalence worldwide. In this
review, we will emphasize the importance of performing
comparative studies to better understand and characterize
Shigella pathogenicity. The development of novel genetic tools
and high-throughput screening and sequencing methods permits
the analysis of Shigella virulence mechanism diversity.
SHIGELLA DIVERSITY: EPIDEMIOLOGY,
GEOGRAPHICAL DISTRIBUTION, AND
EMERGING ANTIBIOTIC RESISTANCE
Shigella remains a leading cause of childhood morbidity and
mortality. The recently conducted case-controlled Global Enteric
Multicenter Study (GEMS) provided a solid update on the
incidence of Shigella among severe forms of diarrhea, and
convincingly demonstrated that in the sites considered (Sub-
saharan Africa, and Asia), Shigella appeared amongst the top
ranking pathogens identified (Kotloff et al., 2013).
Many observations have concluded that Shigella species
are geographically stratified based on the level of economic
development in a given country. S. flexneri is the primary
infectious species in the developing world whereas S. sonnei
rates increase with economic development. S. boydii is most
commonly restricted to Bangladesh and South-East Asia and
rarely occurs outside of these regions. S. dysenteriae type 1 (Sd1)
occurs sporadically in outbreak settings with striking examples
occurring in refugee camps during the civil war in Rwanda
between November 1993 and February 1995 in which more than
180 thousand cases and significant mortality from Sd1 were
recorded (Kernéis et al., 2009). The last major Sd1 outbreak
occurred in 1999 during the civil war in Sierra Leone resulting
in over 4000 cases (Guerin et al., 2004), and the cyclic occurrence
of Sd1 in Bangladesh every 10 years is clearly discontinued for
unknown reasons, illustrating major remaining uncertainties on
changes of epidemiological patterns of these infections.
Outside of outbreak settings, S. flexneri and S. sonnei account
for the majority of Shigellosis cases. Recent epidemiological
studies conducted around the world have discovered a rise in
the proportion of S. sonnei isolates compared to S. flexneri.
The expansion of S. sonnei can clearly be observed from
clinical surveillance studies conducted in China which show the
proportion of S. sonnei isolates increasing from 17.4% in 2003–
2004 to 58.2% less than a decade later, closely following the
rapid industrialization in China (Figure 2; Mao et al., 2013; Qiu
et al., 2015). Noticeably, regions that had undergone significant
industrialization reported decreases in S. flexneri and increasing
cases of S. sonnei compared to under developed areas where
flexneri levels remain high (Qiu et al., 2015). Rising cases of
S. sonnei have also been detected in Bangladesh, which has
historically been affected by all four species of Shigella. Between
2001 and 2011 the proportion of S. sonnei infections rose from 7
to 25% of reported cases in Bangladesh, which also corresponds
with enhanced sanitation and clean water efforts throughout the
country (Das et al., 2013; Hulland et al., 2013). The reasons for
the counter-intuitive increase of S. sonnei in the face of better
sanitation have not been determined, however several hypotheses
have been put forward (Thompson et al., 2015). S. sonnei and
Plesiomonas shigelloides share a common O-antigen that may
lead to natural cross-protective immunity in populations that
encounter high levels of P. shigelloides due to contaminated water
supplies (Sack et al., 1994). Other avenues of interest include
observations of increased survival and replication of S. sonnei
in Acanthamoeba which may act as a reservoir and increased
ability to acquire antibiotic resistances (Saeed et al., 2012). As
more countries increase their level of development and sanitation
it is likely that S. sonnei will become even more of a global public
health concern which could have important impacts on vaccine
development efforts.
A major concern surrounding Shigella is its capacity to
rapidly acquire antibiotic resistances. Development of resistance
to antibiotics is common in all Shigella species, particularly in
S. sonnei, which can acquire resistance genes directly from E.
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FIGURE 2 | Prevelance of Shigella species across China 2003–2013.
Comparison of reported Shigella species between 2003–2004 and
2011–2013 showing the increase in S. sonnei isolations. For years 2003–2004
n = 235 cases, for 2011–2013 n = 1049 cases. Prevelance data reported in
Qiu et al. (2015).
coli through horizontal gene transfer. Several recent reports have
suggested that S. sonnei is capable of sharing resistance plasmids
through conjugation with commensal E. coli (Qu et al., 2014;
Rashid and Rahman, 2015). Recently, S. sonnei resistance to the
frontline antibiotic, ciprofloxacin, has been associated with travel
to Asia and India and has been imported to the United States
(Bowen et al., 2015; De Lappe et al., 2015; Kim et al., 2015).
Preventing the global spread of resistant S. sonnei strains presents
a significant public health challenge as intercontinental travel has
become common.
Antibiotic resistance in S. flexneri is also well-documented
with many studies finding high rates of resistance to at least
one common antibiotic such as ampicillin, tetracycline, and
chloramphenicol (Khaghani et al., 2014; Cui et al., 2015). These
studies show that without access to proper testing facilities or
multiple different antibiotics, patients affected by S. flexneri in
developing countries have a high chance of not being successfully
treated.
Two articles have shed some light on the expansion and spread
of antibiotic resistance in Shigella. Sequencing and phylogenetic
studies have pinpointed the emergence of S. sonnei from a single
European clone that spread pandemically to multiple continents,
diversifying and acquiring multiple antibiotic resistances along
the way (Holt et al., 2013). The sequencing data also suggest that
antibiotic resistant S. sonnei strains have been exported to new
areas via infected travelers. In contrast, Connor et al. recently
published results from a whole genome sequencing study of
S. flexneri that found considerable independent acquisitions of
antibiotic resistance yet little global spread of resistant flexneri
strains, instead favoring a model of local resistance acquisition
and persistence rather than pandemic spread (Connor et al.,
2015). These complementary studies have yielded the clearest
information to date on how Shigella has spread throughout the
global community. Taken together a prediction can be made
that efforts to combat the spread of antibiotic resistance should
focus more heavily on S. sonnei surveillance while more localized
efforts are needed to combat resistance in S. flexneri.
The changing dynamics of Shigella species, particularly trends
like the disappearance of Sd1 and transition from S. flexneri to
S. sonnei raise important unanswered questions. Thus, far, the
molecular and cellular mechanisms of Shigella pathogenesis have
largely considered the invasion step and likely do not account
for the major differences among the four subgroups. Instead,
research probing the early steps of establishment/colonization
may provide new insights into explaining the epidemiological
observations.
FIRST BARRIERS TO SHIGELLA
INFECTION: THE MICROBIOTA AND THE
MUCUS LAYER
Shigella specifically invades the human colon, but not the
small intestine. The molecular basis of this specificity remains
unknown. Prior to reaching the epithelial lining, Shigella have
to survive in the GI environment, to outcompete the colonic
luminal commensal bacteria and to disrupt a thick protective
mucus layer. For a long time, the mucus layer was considered as
the first barrier to Shigella infection: it appears to be the second,
the microbiota standing as the first. The inflammatory response
induced by Shigella invasion might result in a perturbation of the
composition and the function of these barriers, although these
aspects are not yet well-described.
First Barrier: The Microbiota
The gut microbiome of healthy individuals comprises the
most complex interface between microbes and human tissues
in the body. Over 1000 different species of bacteria reside at
varying amounts and locations throughout the GI tract and
70% of the host immune system is dedicated to maintaining
its integrity (Vighi et al., 2008; Rajilic´-Stojanovic´ and de
Vos, 2014). The colonic microbiota can vary significantly
between individuals but is dominated at the phyla level by
Bacteroidetes (∼30%) and Firmicutes (∼30%), with lower levels
of Proteobacteria, Fusobacteria, Actinobacteria, Cyanobacteria,
and Verrucomicrobia (Bäckhed et al., 2005; Andersson et al.,
2008; Arumugam et al., 2011; Sankar et al., 2015; Figure 3). The
microbiota is further stratified based on proximity to the mucosal
lining of the colon with genera such as Coriobacteriaceae,
Lachnospiraceae, and Ruminococcaceae showing greater
abundance in the mucus layer whereas Bacteroidaceae is more
prevalent in the lumen of the intestine (Lavelle et al., 2015).
Significant amounts of research have worked to characterize the
role of the gut microbiome in both health and disease states and
a picture of this complex community is beginning to take shape.
The study of how pathogens interact with and supplant host
commensal bacteria is fast becoming an area of intense research.
These interactions generally occur at the earliest stages of disease
and set up the environment for a pathogen to gain entry into
host tissues. Currently, very few studies have investigated the role
of the microbiota in Shigella infections. The infectious dose of
Shigella is thought to be quite low, (∼10) organisms, so it is likely
that Shigella has evolved some mechanism(s) to survive while
being vastly outnumbered.
Early works assessed the role of individual commensal
organisms in preventing the colonization of Shigella. Germ free
mice and Guinea pigs monocolonized with E. coli were shown to
block the establishment of S. flexneri whereas monocolonization
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FIGURE 3 | During Shigella infection, the colonic microbiota and mucus layers stand as the first barriers protecting the epithelium lineage. (A) The
microbiota colonizes the colonic lumenal compartment, and the outer mucus layer. The inner mucus sterile remains sterile probaly due to its mechanical properties
and accumulation of secreted antimicrobial peptides (AMPs). (B) Shigella secrete proteins belonging to the SPATE family, including Pic characterized in S. flexneri 2a
(Henderson et al., 1999; Gutiérrez-Jiménez et al., 2008; Navarro-Garcia et al., 2010; Ruiz-Perez et al., 2011) and SepA identified in S. flexneri 5a (Benjelloun-Touimi
et al., 1995). Shigella SPATE proteins cleave mucins to allow the bacteria to reach the epithelial layer. Shigella Type III secretion apparatus (T3SA) is required for
epithelium invasion.
with Bacteroides, Bifidobacterium, or Streptococcus had no effect
on Shigella levels (Formal et al., 1961; Maier and Hentges,
1972). Other studies have shown treatment with streptomycin
produces an environment that supports Shigella colonization
in mice (Pongpech et al., 1989; Martino et al., 2005). Together
these studies suggest a complex interplay between Shigella and
commensal bacteria that are not easily reconciled with the
low infectious dose observed in humans. It is possible that
the overwhelming inflammatory environment produced during
human disease masks more subtle and complex early interactions
between Shigella and commensal bacteria. Revisiting these issues
with newer techniques will be important in deciphering the role
of host microbiota in Shigellosis.
The production and resistance to secreted small molecule
inhibitors such as colicins mediate one common form of
competition between enterobacteraceae. Colicins are small,
secreted proteins that can have various cytotoxic properties
against phylogenetically related bacteria and are are almost
always carried on plasmids that encode both the colicin and
its cognate immunity factor, reviewed in Cascales et al. (2007).
Strains that are capable of producing a colicin are better able to
compete against colicin sensitive strains over ecological niches. In
the case of S. sonnei, it has been reported that up to 93% of tested
strains in Kolkata, India, harbor at least one colicin-encoding
plasmid which were shown to target closely related susceptible
E. coli strains, which as previously mentioned, were important
for restricting Shigella colonization (Calcuttawala et al., 2015).
Meanwhile, the chromosomally encoded O-antigen chain length
regulator WzzB was recently reported to contribute to colicin
E2 resistance in S. flexneri (Tran et al., 2014). Regulation of
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the O-antigen chain length has an important impact during the
intracellular phase of Shigella infection, but Tran et al. suggest
the exact number of repeat units has evolved to help mediate
colicin resistance as well (Morona et al., 2003; Tran et al., 2014).
The production and resistance to colicins by Shigella may have an
important role in its initial competition with the host microbiota.
A growing number of reports suggest that members of
the lactobacilli genus may contribute to colonization resistance
against Shigella strains by inducing an anti-inflammatory state
or by blocking adherence to epithelial cells (Tien et al., 2006;
Moorthy et al., 2010; Zhang et al., 2012). Specifically, proteins
found in the S-layers of gram positive Lactobacillus species have
been found to inhibit adhesion of several different pathogens
including Salmonella enteritidis, EHEC O157:H7, and S. sonnei
to tissue culture cell lines although the exact mechanism(s)
remains to be discovered (Golowczyc et al., 2007; Johnson-Henry
et al., 2007; Zhang et al., 2012). Further assessments of the
interaction of commensal bacteria with Shigella will be important
to gain a more complete picture of how beneficial bacteria aid in
host defenses against pathogens. Similarly, studies probing how
Shigella overcomes the resident microbiota during successful
infection would be of great interest.
Second Barrier: The Mucus Layer
A complex layer of mucus naturally protects human epithelium
in the gastrointestinal tracts (stomach, small intestine, colon;
Ambort et al., 2012). The role of the mucus layer is to prevent
direct interaction between commensal bacteria and epithelial
cells (Johansson et al., 2011), avoiding further stimulation of
the immune system (Pelaseyed et al., 2014; Figure 3 upper
panel). In addition to the barrier effect created by the mucus
layer, antimicrobial peptides (AMPs) secreted by epithelial
and phagocytic cells accumulate in the mucus layer and act
as a further inhibitory blockade against microbial species
(Meyer-Hoffert et al., 2008). Mucus is mainly composed
of mucins (20 identified mucins in humans) reviewed in
McGuckin et al. (2011), which are high-molecular weight (1–
10 million Da) glycoproteins linked with each other through
intermolecular disulfide-bonds between cysteine-rich D domains
located in mucins amino and carboxyl termini. Mucins are either
oligomeric, soluble and secreted (MUC2, MUC5ac, MUC5b,
MUC6, and Muc7) or are membrane tethered, which might
be associated with different functions. Mucins are naturally
produced and released on epithelial surfaces: mainly by goblet
cells but also (in a lesser extent) by epithelial cells. It has
been recently shown that the surface colonic goblet cells secrete
continuously, while the secretion of goblet cells located in the
small intestine or colonic crypts are inducible (Birchenough et al.,
2015). The thickness of the mucus layer varies along the GI tract
in humans and various animalmodels (Varum et al., 2012).While
the ileal mucus layer is thin (<300µm), the thickness of the colon
mucus layer can reach 1 mm in humans. The colonic mucus
layer is organized in two layers: the inner layer (50 µm) is firmly
attached to the epithelium, the outer loose layer (>100 µm) is
unattached (Figure 3). Several studies have described the ability
of commensal bacteria to colonize and adhere to the abundant
O-glycans present in the outer mucus layer, while the inner
mucus layer remains sterile, due to its mechanical properties or
capacity to retain secreted antimicrobial compounds, avoiding
further stimulation of epithelial cells by commensal bacteria
(Johansson et al., 2011). The sterility of the inner mucus layer
might be altered by impairment of AMP production leading to
colitis or other inflammatory bowel conditions (Kocsis et al.,
2008; Johansson et al., 2014). The colonic mucus layer backbone
is mainly composed of MUC2 (Karlsson et al., 1996), associated
with MUC5AC and MUC6 (reviewed in McGuckin et al., 2011;
Figure 3). Differential MUC2 glycosylation profiles are described
in the ileum and in the colon, being enriched in either sialilated
or sulfated oligosaccharide species respectively (Karlsson et al.,
1996; Robbe et al., 2003). It has been shown that S. dysenteriae 1
adheres to human colonic mucins, not to small intestine mucins
(Sudha et al., 2001), although no specific adhesion molecule has
been identified.
Shigella efficiently invade the colon, which is protected by
the thickest layer of mucus in the GI tract. In addition, it has
been shown that S. dysenteriae infection induces the expression
of MUC2 and MUC5AC in vitro in an IL-1β dependent-manner
(Prakash et al., 2011; Raja et al., 2012), but also in vivo in a rat
ileal loop model (Gopal et al., 2014). Similarly, S. flexneri induces
MUC2, MUC5AC, MUC4, and MUC15 expression in vitro
(HT29-MTX cells; Sperandio et al., 2013). Together with the fact
that Shigella are devoid of flagella (which promote the mobility
of various pathogens, such as Helicobacter pylori (Ottemann and
Lowenthal, 2002), it suggests that Shigella express and releases
mucolytic molecules allowing its progression through the mucus
layer.
It has long been known that the degradation of the mucus
outer layer and the release of mucin glycans, by glycoside
hydrolase-expressing bacteria composing the microbiota, were
used as a source of nutrients and energy (Deplancke et al., 2002;
Sonnenburg et al., 2005). So far, no report describes similar
adaptation of Shigella in the colonic lumen to promote its
proliferation.
Mucus integrity can be altered by the several classes of
enzymes secreted by enterobacteria (Figure 3 lower panel).
It includes mucinases, glycosidases, sulfatases, sialidases (or
neuraminidases), and sialilate O-acetylesterases (SIAE; Corfield
et al., 1992; reviewed in McGuckin et al., 2011; Corfield, 2015).
It was shown by Haider and colleagues that all four Shigella
species were able to produce mucinases and neuraminidases
(Haider et al., 1993), although since this initial observation no
comparative study was performed. Pic, a S. flexneri 2A (4257T)
autosecreted protein belonging to the SPATE (Serine Protease
Autotransporters of Enterobacteriaceae) was characterized as
a mucinase (Henderson et al., 1999; Gutiérrez-Jiménez et al.,
2008). It was shown that the deletion of pic in S. flexneri
2a clinical isolates reduced its pathogenicity (Navarro-Garcia
et al., 2010; Zhang et al., 2013). Pic homologous protein is
expressed by S. sonnei, not in S. flexneri 5a, which instead
secretes another protein belonging to the SPATE family (SepA),
whose function remains unknown (Benjelloun-Touimi et al.,
1995, 1998). S. dysenteriae, S. flexneri 2a, S. sonnei and S. boydii
express homologous proteins to Enterotoxigenic E. coli (ETEC)
EatA, belonging to the SPATE family, which has been shown to
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5 April 2016 | Volume 6 | Article 45
Anderson et al. New Challenges for Shigella Research
degrade MUC2 (Kumar et al., 2013). Until now, the role of EatA
in Shigella virulence mechanisms has not yet been characterized.
After traversing the mucus layer, Shigella contact and inject
epithelial cells with effector molecules that down-regulate
production of AMPs, supporting an environment that is more
conducive to further penetration into the tissue and providing
evidence that AMPs are an important host defense factor against
Shigella (Sperandio et al., 2008; Gudmundsson et al., 2010).
Altogether, these results suggest that Shigella potentially
express and secrete mucinases, although the specificity of these
enzymes will have to be characterized and their cytotoxicity
further studied. It would also be of great interest to study
the consequences of disrupting of the mucus layer on local
AMP concentrations and inhibition of invading Shigella bacteria.
Disruption of the mucus layer and dispersion of AMPs could
play a significant role in Shigella survival in addition to aiding
colonization.
GLOBAL TOOLS TO DECIPHER SHIGELLA
VIRULENCE MECHANISM DIVERSITY
The advent of affordable, high-throughput sequencing
technologies is allowing the field of microbiology to design
powerful experiments that have previously been impossible to
perform due to time, money, or computing restraints. With
this technology however has come the very real problem of
how to adequately mine the vast quantities of data generated
for important information. In the Shigella field there has
been an explosion in the number of sequenced strains and
phylogenetic trees establishing a detailed history of the evolution
of this pathogen. The most sophisticated sequencing analysis
of S. sonnei to date comprised of 132 strains spread across
four continents has yielded very interesting information on
its origins and recent global spread (Holt et al., 2012). In
this paper the authors estimate the most recent common
ancestor to S. sonnei arose in Europe less than 500 years ago
between 1554 and 1763 A.D (Holt et al., 2012). Additionally,
it was found that the global spread of S. sonnei has only
begun quite recently, since the mid twentieth century (Holt
et al., 2012). A subsequent massive sequencing study of 263
S. sonnei strains, isolated over 15 years in Vietnam, has been
used to track its evolution and to date its first arrival in
the country to the 1980’s (Holt et al., 2013). The result is a
fascinating “high resolution” view of local adaptations and
evolutionary changes that have occurred over the past 15
years from what started as a single imported clone (Holt et al.,
2013). Sequencing studies like these are providing invaluable
information about how pathogens evolve, expand, and become
fixed in a population. However, the massive amount of data
generated from sequencing so many isolates can present a
daunting challenge to mine for insights into the functional
outcomes of microbial evolution. Holt et al.’s (2012) paper alone
reported detecting 10,111 SNP mutations in the sequenced
strains making it difficult to investigate individual mutations
for their impact on the fitness of Shigella. Ideally, it would be
intriguing to assess Shigella’s pathogenic traits over time based
upon its evolution.
Alternatively, high-throughput sequencing has found another
important use in new generations of mutant library design and
screening applications. In Vibrio cholerae, pooled transposon
mutant libraries have been screened in rich media and under
in vivo conditions, coupled with next generation transposon
sequencing (TN-seq) resulting in a global picture of genes
essential for survival in a rabbit animal model (Kamp et al.,
2013). This global approach allowed over 100,000 individual
mutants to be screened simultaneously in a single model system,
creating a nearly complete picture of the genes required for V.
cholerae to survive in a host (Kamp et al., 2013). This technique
has also successfully been demonstrated in the gram positive
pathogen Staphylococcus aureus, where over 71,000 transposon
mutants were screened in vivo (Valentino et al., 2014). Adapting
this protocol to Shigella, coupled with the newly developed
Guinea pig colonic infectionmodel could give significant insights
into the repertoire of genes needed to survive and replicate in
the colon during infection (Arena et al., 2015). Furthermore,
performing such experiments in representative S. sonnei and S.
flexneri strains could allow for an interesting comparison study,
highlighting similarities, and differences in growth and survival
strategies between Shigella species which up until now have been
impossible to perform.
CONCLUSIONS
For several decades, S. flexneri strains (2a and 5a) were used as
model organisms to characterize Shigella virulence mechanisms.
However, each Shigella groups and subgroups exploit various
virulence mechanisms and as a consequence deserved a specific
analysis. The development of high-throughput technologies
represents a key opportunity to address this fastidious but
essential question without bias. It will allow comparative studies
and a better comprehension of various Shigella group specific
virulence features. This aspect is well-illustrated by the diversity
of SPATE proteins expressed and secreted by different groups
(see Section First Barriers to Shigella Infection: The Microbiota
and the Mucus Layer), coming studies will probably highlight
additional specificities.
The diversity of Shigella groups identified worldwide has
changed over the last decades. Efforts to improve water sanitation
have lead to a decrease in S. flexneri infections however S. sonnei
rapidly moves in replacing S. flexneri. For this reason improving
water supplies alone is not sufficient to eliminate the threat of
Shigella. Vaccines targeting S. sonnei and remaining S. flexneri
serotypes (i.e., 2a, 3a, and 6)+/− S. dysenteriae 1 must be part of
a long-term strategy that takes in account the serotype-specificity
of immune protection against Shigella, to reduce the global
dysentery burden. However, the development of live, rationally-
attenuated, oral vaccine candidates against Shigellosis has been
handicapped by two major issues. (i) The difficulty to assemble
a multivalent set of these epidemiologically-relevant serotypes,
in the absence of a definitely-established cross-protective antigen
(Levine et al., 2007). (ii) A clear discrepancy in the colonization
and potential protective capacity of the so-far tested candidates
when tested in western volunteers and in individuals living in
endemic areas (Coster et al., 1999; Rahman et al., 2011).
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Clearly, more basic research aimed at better understanding the
basic mechanisms of Shigella colonization is warranted to master
this key step and improve the design of future live-attenuated
orally-administered vaccines.
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